Advertisement

Annals of sex research

, Volume 4, Issue 2, pp 117–129 | Cite as

The use of Medroxyprogesterone Acetate to assist in the treatment of sexual offenders

  • Barry M. Maletzky
Article

Abstract

Within a population of 5132 sexual offenders referred to an outpatient sexual abuse clinic, the first 100 cases receiving Medroxyprogesterone Acetate (MPA) as a long-acting intramuscular injection were retrospectively reviewed and compared to a matching cohort which did not receive the drug. MPA appeared to be a safe and effective short-term supplement to an ongoing treatment program emphasizing behavioral, cognitive, group, and family therapy approaches. Data indicate no interference with concurrent treatment approaches and no irreversible side-effects, although caution is advised regarding prolonged use of this medicine, as long term effects of MPA were not examined.

These findings also help in defining the characteristics of sexual offenders who are most likely to need, and to benefit from, MPA. Those with histories of hypersexuality, poor sexual impulse control, developmental disabilities, aggressive sexuality, homosexual pedophilia, multiple paraphilias, and predatory patterns of inappropriate sexual behavior merit consideration for MPA. However, the drug should be employed as an aid, particularly early in therapy, rather than as a treatment by itself.

Findings are offered with the caution that data collection and statistical analyses were relatively unsophisticated. Recommendations for further investigation are offered.

Keywords

Sexual Abuse Family Therapy Sexual Offender Developmental Disability Medroxyprogesterone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bancroft, J. (1977). Hormones and sexual behavior.Psychological Medicine, 7, 553–556.Google Scholar
  2. Barlow, D.H. & Abel, G.G. (1981). Recent developments in assessment and treatment of paraphilias and gender identity disorders. In W.E. Craighead, A.E. Razdin, & M.H. Maharey (eds.)Behavior modification: Principles, issues, and applications, Second edition. Boston: Houghton-Mifflin.Google Scholar
  3. Berlin, F.S. & Meinecke, C.G. (1981). Treatment of sex offenders with antiandrogenic medication: conceptualization, review of treatment and modalities, and preliminary findings.American Journal of Psychiatry, 138, 601–607.Google Scholar
  4. Bradford, J.W. (1983). The hormonal treatment of sexual offenders.Bulletin of the American Academy of Psychiatry and the Law, 11, 159–167.Google Scholar
  5. Cooper, A.J. (1986). Progestogens in the treatment of male sex offenders: A review.Canadian Journal of Psychiatry, 31, 73–79.Google Scholar
  6. Demsky, L.S. (1984). The use of depo-Provera in the treatment of sex offenders.The Journal of Legal Medicine, 5, 295–322.Google Scholar
  7. Freund, K. (1980). Therapeutic sex drive reduction.Acta Psychiatrica Scandinavaca, Supplementum, 62, 5–38.Google Scholar
  8. Gagne, P. (1981). Treatment of sex offenders with Medroxyprogesterone Acetate.American Journal of Psychiatry, 138, 644–646.Google Scholar
  9. Halleck, S.L. (1981). The ethics of antiandrogen therapy.American Journal of Psychiatry, 138, 642–643.Google Scholar
  10. Laschet, V. & Laschet, L. (1975). Antiandrogens in the treatment of sexual deviations of man.Journal of Steroid Biochemistry, 6, 821–826.Google Scholar
  11. Maletzky, B.M. (1991).Treating the sexual offender. Newbury Park, California: Sage Publications.Google Scholar
  12. Meyer, W.J., Walker, P.A., Emory, L.E., & Smith, E.R. (1985). Physical, metabolic, and hormonal effects on men of long-term therapy with Medroxyprogesterone Acetate.Fertility and Sterility, 43, 102–109.Google Scholar
  13. Money, J. (1970). Use of an androgen-depleting hormone in the treatment of male sexual offenders.Journal of Sex Research, 6, 165–172.Google Scholar
  14. Walker, P.A. & Meyer, W.J. (1981). Medroxyprogesterone Acetate treatment for paraphiliac sex offenders. In J.R. Hays, T.U. Roberts, & U.S. Solway (Eds.),Violence and the violent individual. New York: S.P. Medical and Scientific Books, 353–373.Google Scholar
  15. Walker, P., Meyer, W.J., Emory, L.E., & Robin, A.L. (1984). Antiandrogenic treatment of the paraphilias. In H.C. Stancer, P.E. Garfinkel, & V.M. Rakoff (Eds.),Guidelines for the use of Psychotropic Drugs. Jamaica, New York: Spectrum Publications.Google Scholar
  16. Wincze, J.P., Barsal, S., & Malamud, M. (1986). Effects of Medroxyprogesterone Acetate on subjective arousal, arousal to erotic stimulation, and nocturnal penile tumescence in male sex offenders.Archives of Sexual Behavior, 15, 293–305.Google Scholar

Copyright information

© Juniper Press 1988

Authors and Affiliations

  • Barry M. Maletzky
    • 1
  1. 1.Oregon Health Sciences UniversityPortland

Personalised recommendations